Antibiotice sales increased by 6% in H1 2014, while the gross profit rose by 19%
According to the financial results the amount of income from sales recorded in the first half was LEI 149.78 million, up 6% versus the same period of 2013.
Also, the gross profit for the first half of 2014 recorded a positive trend, reaching the value of LEI 21.87 million, by 19 % higher than the gross profit of the first half of 2013, when it stood at LEI 18.44 million.
“We have implemented the strategy and policies defined in the business plan for 2012-2016, so that the good results obtained by Antibiotice in the first half of this year were due both to the policy of broadening its portfolio, as well as to the orientation towards the foreign markets, where the profitability degree has been increasing,” said Ioan Nani, CEO of Antibiotice.
In the first 6 months of 2014 Antibiotice strengthened its position as a principal manufacturer of anti-infective drugs for systemic use (Eficef®, Amoxiplus®, Ampiplus®, Colistin Antibiotice®). However, the products from the following classes had also a significant contribution to the turnover: Dermatological Preparations, +27% (Ekarzin®, Sal-Ekarzin®, Clo-Ekarzin®, Nidoflor®, Cutaden® Bebe), Digestive Tract and Metabolism, +24.1% (Piafen®, Spaverin®, Equilibra®) and Musculoskeletal System, +8.6% (Ibufen® cpr., Aceclofen® sup., Clafen® gel, Saliform® Forte).
Sales increased by 10% in the hospital segment
The first half ended with a 10% increase in the hospital sales as compared to H I 2013. The orientation of the sale structure towards therapeutically valuable drugs combined with effective promotion and selling policies as well as the winning of new customers in the private hospital segment increased the presence of Antibiotice in the hospitals.
7% growth in the export sales
The sales revenues from the foreign markets amounted to LEI 46.8 million in the first half of 2014, up 7% compared to the same period of 2013 when the value was LEI 43.7 million. These results were obtained by selling the active substance Nystatin (51%) and the 70 finished products registered on the external markets (49%).
15% increase in the Nystatin sales, a product for which Antibiotice is a global leader
As regards the export of Nystatin, the company strategy aimed at strengthening and maintaining the global leadership position. Thus, the amount of Nystatin sold in the first half of 2014 increased by 15% as compared to the previous year, the main growing markets being in Asia and Africa.
The main opportunities for this active substance are represented by the three end-users that have been developing the registration process of Nystatin on the US market. These registrations will increase the Nystatin sales to more than USD 1.5 million per year on the US market.
New partnerships for the delivery of finished products
The marketing strategy for the finished products aims aimed at increasing the presence of Antibiotice on the regulated markets. Thus, in the first half of 2014, our company negotiated the commercial terms with the most important injectable generics company in the US for selling two products. Based on the FDA authorization, Antibiotice has been currently running trading relations with another two large distributors in the US market.
At the same time, Antibiotice negotiated and launched new collaborations for penetrating the European markets (France, Poland, the Czech Republic, etc.) with injectables, tablets and semi-solid forms(ointments, creams, gels and suppositories). In these conditions, it is estimated that the exports on the EU markets will significantly increase in the total value of the export turnover in the medium and long term.
In addition to these new projects, initiated in the first half of 2014, Antibiotice has been negotiating commercial contracts for the access of finished products on new markets in Central Asia, South Africa, South Saharan Africa (Ethiopia, Angola).
The main destinations of the Antibiotice products in terms of their contribution to the turnover were: Europe (France, Hungary, Germany), the United States of America, The Middle East, Russia and other CIS member countries (Azerbaijan, Georgia, Moldova), Asia, Africa.
Antibiotice in the first half of 2014
– the 5th place among the top manufacturers of generic drugs without medical prescription in Romania, recording a 5% increase in the market share in the second quarter (6.4 %) compared to the first quarter (6.1 %);
– the 12th place in the pharmaceutical market, with a 2.58% market share in the Q2, higher by 4.5% compared to the Q1, when the value was 2.47%;
– sales revenue up 6% compared to the H1 2013;
– gross profit up 19% compared to H1 2013;
– operating profit up 23% compared to H1 I 2013.